Genmab A/S: Capital Increase and Market Response

Capital Increase

On 12 May 2026, Genmab A/S announced a capital increase resulting from the exercise of employee warrants. The transaction was reported by GlobeNewswire and Nasdaq OMX Nordic, indicating that the company’s share capital was expanded through the issuance of new shares. No additional financial details such as the amount raised or the number of shares issued were disclosed in the available sources.

Market Reaction

The news prompted a series of market movements:

  • Stock Price: On 11 May, Genmab shares experienced a significant decline, falling 12 % at one point during the trading day. By the following Monday, the price had recovered, showing a rebound in the afternoon session.
  • Trading Volume: The stock was included in the Danish elite index (C25) on 11 May, alongside Novo Nordisk and Zealand Pharma, contributing to the index’s positive performance that day.
  • Analyst Sentiment: Following the Friday decline, analysts characterized the price drop as “over‑dramatic.” Deutsche Bank later adjusted its target price to 2 250 DKK (previously 2 400 DKK) but maintained a buy recommendation. Nordea also reiterated a buy recommendation with a target of 2 015 DKK. Jefferies reiterated a buy rating after the company’s first‑quarter earnings and pipeline updates.

Analyst Recommendations

  • Nordea: Buy, target price 2 015 DKK.
  • Deutsche Bank: Buy, target price 2 250 DKK (down from 2 400 DKK).
  • Jefferies: Buy, following investor commentary on the research pipeline.

No other analyst ratings were reported in the provided sources.

Short Positions

An overview of short positions in Danish stocks, as of 12 May 2026, listed Genmab among other companies. However, the short‑position data did not specify the net short percentage for Genmab, only for Zealand Pharma (10.07 %) and a few other firms. Therefore, the short interest for Genmab remains unspecified in the available information.

Company Fundamentals

Genmab A/S is a biotechnology firm listed on the OMX Nordic Exchange in Copenhagen (currency DKK). As of 10 May 2026, the share closed at 1 659 DKK, with a 52‑week high of 2 257 DKK and a 52‑week low of 1 268.5 DKK. The market capitalization stands at 100 770 000 000 DKK and the price‑earnings ratio is 19.73. The company specializes in antibody therapeutics for cancer treatment and has been publicly traded since 18 October 2000.